Recent News

• 06.11.2025 - Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
• 06.11.2025 - Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
• 06.05.2025 - 2025 Jefferies Global Healthcare Conference
• 06.02.2025 - Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
• 06.02.2025 - Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
• 05.30.2025 - Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
• 05.30.2025 - Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
• 05.23.2025 - Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
• 05.23.2025 - Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
• 05.22.2025 - Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

Recent Filings

• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2025 - 8-K Current report
• 05.27.2025 - 8-K Current report
• 05.27.2025 - EX-99.1 EX-99.1
• 05.22.2025 - 8-K Current report
• 05.22.2025 - EX-99.1 EX-99.1